Introduction
Hypertrophic cardiomyopathy (HCM) is a genetically determined myocardial disease. 1 The spectrum of clinical phenotypes and natural history includes a group at high risk for sudden death (SD). 1−7 Clinical studies have recently focused on the risk stratification and appropriateness of preventive measures. 8, 9 However, limitations of these studies are related to low disease prevalence and the fact that patients at risk for SD are often young and asymptomatic with a low incidence of unpredictable, lethal events. 9 Therefore, even in a single patient, long-term follow-up may help to clarify some aspects of the natural history of disease and of the SD mechanisms in a patient with HCM.
This case refers to a 39-year-old woman with hypertrophic obstructive cardiomyopathy (HOCM) who has been followed since 1977. She was first referred for cardiological evaluation at age 16 years due to atypical chest pain. Her father died (age of 50 years) as did two sisters (age 2 and 9 years) and two brothers (age 16 and 17 years).
A HOCM with a septum thickness of 15 mm and a conduction of 1:1 during atrial pacing up to 200 beats/min were observed. At this atrial rate the AH interval passed from 55 to 160 ms.
Eight years later (1985) at further evaluation the septum thickness was 18 mm. Holter monitoring elicited rare monomorphic premature ventric-ular beats (10 in 24 hours). Transesophageal atrial stimulation (stimuli with 9.9 duration and 20-mA current intensity) showed 1:1 atrioventricular (AV) conduction with narrow QRS up to a rate of 190 beats/min with an increase of the stimulus to R interval from 120 to 200 ms. Five seconds after the onset of atrial stimulation at 200 beats/min a premature ventricular 3-beat run was followed by ventricular fibrillation (VF). Prior to VF an increasing ST depression was observed.
Amiodarone (600 mg/day) or verapamil (120 mg three times a day) treatment prevented VF induction. After withdrawal of either drug, VF was induced again by transesophageal atrial pacing at 190 beats/min. 10 The patient remained asymptomatic while taking verapamil until 1996, when she was submitted to a new evaluation, including a programmed ventricular stimulation which induced a polymorphic, sustained, syncopal ventricular tachycardia (VT). Therefore, a single chamber cardioverter defibrillator (model Medtronic 7221, Minneapolis, MN, USA) was implanted in a subcutaneous left pectoral pocket.
The patient was followed and the device interrogated every 6 months. No events were reported by the device for 4 years and she remained asymptomatic, autonomously suspending drug therapy. At the last interrogation (November 2000) the device reported one event. The episode interval plot ( Fig. 1 ) and the electrogram (EGM) marker strip ( Fig. 2) showed atrial fibrillation (AF) with RR intervals ranging between 500 and 270 ms followed by VF. The diagnosis of AF, given the absence of atrial EGMs in the single chamber device, was supported by the analysis of the RR interval and of the PACE, Vol. 26 FAVALE, ET AL. morphology of the six ventricular EGMs preceding VF which were similar to those recorded during sinus rhythm. AF and VF were terminated by the implantable cardioverter defibrillator (ICD) with a 32-J shock. While sleeping (4:27 AM) the patient did not sense the ICD intervention.
SD occurs in young, asymptomatic patients with HCM, and has a reported annual mortality rate ranging from 4% to 6% percent. [11] [12] [13] [14] [15] Secondary prevention with an ICD in patients who have had episodes of sustained VT or resuscitated VF is mandatory due to the high incidence of lifethreatening arrhythmias. 9 The indication for ICD is related to low risk/benefit and favorable cost effectiveness ratios achieved by the latest generation of pectorally implantable devices in high risk patients.
The role of ICD for primary prevention of SD in patients who have not had prior cardiac arrest or spontaneous sustained VT needs to be defined. A retrospective, multicenter study evaluated the arrhythmic events of HCM patients with an ICD implanted solely for primary prevention due to one or more of the following SD risk factors: syncope, a family history of SD, nonsustained VT, sustained VT induced during electrophysiological testing and a left wall thickness of ≥30 mm. The reported 5% annual rate of appropriate ICD discharges for high rate VT or VF is similar to the rate of SD in selected high risk patients with HCM.
9,11-15 The case described in this article presents two interesting aspects related to primary prevention. The first is patient risk profile, the second the mechanism by which aborted SD occurred. In this case the risk profile included a family history of SD and an interventricular septum thickness of 18 mm. A family history of SD at young age, defined as at least two SDs in primary, related, family members, is considered an indicator of high risk. 16 A prophylactic implantation of ICD in these patients may be considered although no data are reported on its preventive efficacy: a better quality-of-life due to the patients' greater sense of security may also be expected. 2 The wall thickness is another strong independent predictor of SD. 17 At present, malignant family history and wall thickness would be considered sufficient to indicate an ICD implantation in a patient with HCM. However, in 1996, in this case a sustained VT induction with ventricular programmed stimulation preceded the ICD implantation. Although nonpredictive in HCM, VT inducibility is considered a marker of high risk for SD; moreover, in this case the induction of VF during high rate atrial pacing was considered an additional prognostic marker due to the high incidence of atrial tachyarrhythmias in HCM. The mechanism of the aborted arrhythmic death recorded by the ICD, a spontaneous episode of high rate AF degenerating into VF, was similar to that observed in 1985 during high rate atrial stimulation. Therefore, the incremental atrial pacing during electrophysiological study elicited the future mechanism of death. The combination of hemodynamic and electrical mechanisms may be responsible for VF induction. Patients with HCM are often unable to maintain stroke volume at higher rates due to the shortened time for filling a poorly relaxing and noncompliant ventricle. This effect is added to, and in some way responsible for, the electrical instability that is related to the extent and severity of myocardial disarray.
This long-term single case is not sufficient for drawing general conclusions; however, it must be taken into consideration because of the limited size of the HCM population and the low rate of events render large scale studies difficult. With this in mind, two points merit highlighting in future studies: the first concerns the clinical role of incremental atrial stimulation for stratifying subgroups at higher risk for SD, and the second regards the impact of ICD indications for primary prevention on long-term survival.
The current risk to benefit ratio allows a wider use of ICDs that, given their memory capability, may clarify clinically unresolved issues. An accurate risk stratification of patients with HCM for primary prevention of SD is mandatory for increasing the efficiency of ICD therapy.
